Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec
17/03/2026 12:14
March 17 (Reuters) - Candel Therapeutics Inc CADL.O: CANDEL THERAPEUTICS INC: EXTENDED SURVIVAL TAIL OBSERVED IN TRIAL OF AGLATIMAGENE BESADENOVEC CANDEL THERAPEUTICS INC: PHASE 3 PIVOTAL STUDY PLANNED FOR INITIATION IN Q2 2026 Source text: ID:nGNXc45RNl Further company coverage: CADL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec